Table 3

Multivariate analysis
PSA Progression-Free Survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 1.41 (0.67-2.97) 0.4 1.26 (0.59-2.68) 0.5 1.30 (0.61-2.79) 0.5
Extra-prostatic extension
Yes 1.0 1.0 1.0
No 3.33 (1.31-8.49) 0.01 3.21 (1.28-8.07) 0.01 3.21 (1.27-8.09) 0.01
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.56 (0.69-3.56) 0.3 1.38 (0.60-3.14) 0.4 1.40 (0.61-3.18) 0.4
Surgical margins involved
No 1.0 1.0 1.0
Yes 0.75 (0.31-1.79) 0.5 0.72 (0.31-1.67) 0.4 0.68 (0.29-1.62) 0.4
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 0.77 (0.35-1.68) 0.5 0.64 (0.28-1.43) 0.3 0.64 (0.28-1.42) 0.3
Gleason score
<7 1.0
≥7 2.03 (0.91-4.55) 0.08
Gleason score
≤7 1.0
>7 3.29 (1.63-6.65) 0.001
Gleason score
<7 1.0 0.003
=7 1.33 (0.54-3.26) 0.5
>7 3.90 (1.59-9.55) 0.003
Epithelial IRS
>2 1.0 1.0 1.0
≤2 6.20 (1.30-29.44) 0.02 4.85 (0.98-24.09) 0.05 4.86 (0.98-24.05) 0.05
Stroma IRS
<12 1.0 1.0 1.0
=12 2.06 (0.87-4.88) 0.1 1.90 (0.77-4.65) 0.1 1.84 (0.76-4.50) 0.6

Abbreviations:HR, Hazard Ratio;CI,Confidence Interval;PSA,Prostate-specific antigen;IRS,Immuno-reactive score.

Nuzzo et al.

Nuzzo et al. BMC Cancer 2012 12:625   doi:10.1186/1471-2407-12-625

Open Data